Increased ABeta production or accumulation is considered major factors in the development of Alzheimer's disease (AD). ApoE4 dosage, considered a major risk factor for Alzheimer's disease, increases ABeta40 accumulation by reducing Abeta degradation, while presenilin mutations increase the risk of Alzheimer's disease by increasing Abeta production. The mechanism of ABeta-toxicity in vivo is not well understood, and a lack of consistent correlation between ABeta-deposits and dementia further confounds the issue. An understanding of how A is degraded will help understand how it can be toxic in vivo. In preliminary experiments, inhibition of lysosomal degradation of ABeta increases both neuronal Abeta staining and toxicity in vivo, whereas a decrease in extracellular ABeta deposits using multiple approaches sometimes reduces acute toxicity. This proposal will test the hypothesis if endosomal/lysosomal ABeta accumulation can cause direct neurotoxicity, while extracellular ABeta leads to neurotoxicity secondary to inflammation. A lipoprotein carrier based ABeta infusion model will be used to obtain widespread AB deposits and neurotoxicity.
Aim 1 will test the hypothesis if limiting intracellular degradation with inhibitors of cathepsins D or B will increase intracellular accumulation of AB and induce toxicity by endosomal/lysosomal leakiness, cathepsin upregulation, and caspase activation.
In Aim 2, extracellular degradation of ABeta will be inhibited to test the hypothesis if extracellular ABeta accumulation and deposition causes less acute neurotoxicity associated with inflammation.
Aim 3 will test if lipoprotein carrier protein deletions that limit the receptor-mediated uptake of ABeta increase extracellular deposition but reduce intracellular ABeta accumulation and neurotoxicity.
Aim 4 will evaluate if age-related defects in intracellular degradation increase ABeta accumulation and toxicity.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG016793-02
Application #
6372350
Study Section
Special Emphasis Panel (ZRG1-BDCN-3 (01))
Program Officer
Snyder, D Stephen
Project Start
2000-09-01
Project End
2005-08-31
Budget Start
2001-09-01
Budget End
2002-08-31
Support Year
2
Fiscal Year
2001
Total Cost
$189,000
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Frautschy, Sally A; Cole, Greg M (2011) What was lost in translation in the DHA trial is whom you should intend to treat. Alzheimers Res Ther 3:2
Frautschy, Sally A (2010) Thinking outside the box about COX-1 in Alzheimer's disease. Neurobiol Dis 38:492-4
Cole, Greg M; Frautschy, Sally A (2010) Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. CNS Neurol Disord Drug Targets 9:140-8
Frautschy, Sally A; Cole, Greg M (2010) Why pleiotropic interventions are needed for Alzheimer's disease. Mol Neurobiol 41:392-409
Ma, Qiu-Lan; Galasko, Douglas R; Ringman, John M et al. (2009) Reduction of SorLA/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer disease cerebrospinal fluid. Arch Neurol 66:448-57
Hu, Shuxin; Begum, Aynun N; Jones, Mychica R et al. (2009) GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol Dis 33:193-206
Hu, Shuxin; Ying, Zhe; Gomez-Pinilla, Fernando et al. (2009) Exercise can increase small heat shock proteins (sHSP) and pre- and post-synaptic proteins in the hippocampus. Brain Res 1249:191-201
Ma, Qiu-Lan; Harris-White, Marni E; Ubeda, Oliver J et al. (2007) Evidence of Abeta- and transgene-dependent defects in ERK-CREB signaling in Alzheimer's models. J Neurochem 103:1594-607
Zhao, Lixia; Ma, Qiu-Lan; Calon, Frederic et al. (2006) Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat Neurosci 9:234-42
Lim, Giselle P; Calon, Frederic; Morihara, Takashi et al. (2005) A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 25:3032-40

Showing the most recent 10 out of 14 publications